The Pharma Data

DECEMBER 16, 2020

Good CV Health Metrics From Midlife May Lower Dementia Risk. 16, 2020 — Having an ideal or intermediate level of global cardiovascular health (CVH) metrics from midlife to later in life is associated with a reduced risk for dementia , according to a study published online Dec. Professional. WEDNESDAY, Dec. 15 in PLOS Medicine.

Medicine 52

Medicine Research 52

pharmaphorum

NOVEMBER 30, 2021

Japanese drugmaker Eisai has teamed up with Fujitsu spin-out FCNT, which makes smartphones aimed at older consumers, on digital tools to support people with dementia. The post Eisai forges alliance with FCNT on digital tools for dementia appeared first on. The network already has 2.4

Development 58

Development Licensing Licensing Trials 58

Pharma Marketing Network

DECEMBER 6, 2021

NEW YORK, December 6 th , 2021 (PRNEWSWIRE) – Tap Native, the leading health-focused content discovery platform, today unveiled a list of the top 20 most popular health topics viewed by consumer audiences in 2021. million unique URLs across the top 100 largest health websites in its network to determine which topics were viewed most.

Engineer 52

Engineer Vaccination Vaccine Production 52

pharmaphorum

MARCH 21, 2022

Eli Lilly is investing $700M into genetic medicine, announcing plans to establish a Boston research center, and with the acquisition of Prevail Therapeutics in late 2020, Lilly secured access to two gene therapies that had already advanced into human testing — with one targeting Parkinson’s disease and the other, dementia.

Genetics 52

Genetics Development Drugs Gene Therapy 52

pharmaphorum

MARCH 19, 2021

Protein misfolding has become a hot topic in the biopharma industry, with a clutch of emerging companies targeting the broad range of diseases that feature aberrant proteins.

Protein 103

Protein Gene Editing Drugs Clinical Trials 103

Rethinking Clinical Trials

AUGUST 29, 2022

The series will include an additional 5 moderated webinar discussions with panels of experts.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Rethinking Clinical Trials

AUGUST 10, 2022

The series will include an additional 5 moderated webinar discussions with panels of experts.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

pharmaphorum

NOVEMBER 28, 2022

Then, we discuss the topic of ESG. Yet, treatments that extend lifespans must also note how that pertains to later life, to care therein and illness, including arthritis and dementia – often extending to hospice care. Again, the importance of patient trust comes into the conversation.

Marketing 98

Marketing 98

The Pharma Data

JANUARY 4, 2021

When adjusting for socioeconomic position, medical comorbidities, and dementia, the risk for suicide was higher in patients with PD than control participants (hazard ratio [HR], 2.1). Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. per 100,000) died by suicide. © 2021 HealthDay.

HR 52

HR Research 52

The Pharma Data

DECEMBER 28, 2020

22 in Alzheimer’s & Dementia. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. MONDAY, Dec. 28, 2020 — Longer time to fall asleep is associated with greater subsequent cognitive decline among middle-aged Hispanic adults, according to a study published online Dec.

Medicine 52

Medicine Research 52

The Pharma Data

NOVEMBER 23, 2020

of the Stanford University School of Medicine in California, and colleagues found a strong bidirectional association between self-reported visual impairment and dementia over time. These include the use of special contact lenses and spectacles, increased time spent outdoors, and use of topical low-dose atropine drops.”

Development 52

Development Clinical Trials Clinical Trials Research 52

Drug Discovery World

MARCH 8, 2024

The FDA has said it hopes to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design of the TRAILBLAZER-ALZ 2 study.

Trials 52

Trials FDA Approval Drugs Clinical Trials 52

The Pharma Data

NOVEMBER 6, 2020

6, 2020 — For individuals with prodromal Alzheimer disease, a multinutrient intervention can slow cognitive decline, according to a study recently published in Alzheimer’s & Dementia. 60 percent; between-group difference, 0.212), Clinical Dementia Rating-Sum of Boxes (?45 FRIDAY, Nov. Hilkka Soininen, M.D.,

Production 40

Production Research Trials 40

The Pharma Data

JANUARY 15, 2021

Longitudinal memory assessments were performed in 17 PPA patients with evidence of AD on autopsy or biomarkers and in 14 patients with amnestic dementia of the Alzheimer type with AD at autopsy (DAT-AD). Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. Marsel-Mesulam, M.D.,

Medicine 52

Medicine Research 52

The Pharma Data

DECEMBER 23, 2020

percent in the lowest and highest quintile regions, respectively; most of the difference was due to dementia, pain, and stroke conditions seen by neurologists. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. Overall, 23.5 © 2020 HealthDay. All rights reserved. Source link.

Research 52

Research 52

VirTrial

JANUARY 2, 2024

As the global leaders in CNS research optimization for over 20 years with proven endpoint quality solutions supported by renowned leaders in dementia, schizophrenia, Parkinson’s research and more, Signant is well-positioned to continue helping sponsors tackle the toughest challenges in neuroscience.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 26, 2020

26, 2020 — Rural Medicare beneficiaries with Alzheimer disease and related dementia (ADRD) spend more time in nursing homes, receive less home health care, and have shorter survival than their urban counterparts, according to a study published online Oct. Professional. Rural Patients With Alzheimer Disease Have Shorter Survival.

Nurses 52

Nurses Research 52

pharmaphorum

APRIL 4, 2022

The uncovered genes also confirmed the importance of amyloid beta and tau proteins, which have been the focus of much of the drug discovery effort in Alzheimer’s for the last couple of decades, albeit with limited results and just one approved therapy – Biogen’s Aduhelm (aducanumab) – whose efficacy is a topic of considerable debate.

Gene 52

Gene Genetics Research Development 52

XTalks

JULY 27, 2021

The Alzheimer’s Association International Conference (AAIC) 2021 is being held this week and the controversial approval of Biogen’s Aduhelm (aducanumab) is among the topics front and center at the largely virtual meeting this year.

Antibody 98

Antibody Drugs Trials Clinical Trials 98

The Pharma Data

JANUARY 10, 2021

Ilya Pharma completed recruitment in its Phase I trial of ILP100-Topical for wound treatment. BioXcel Therapeutics announced that its dexmedetomidine hit the primary and secondary endpoints of the TRANQUILITY Phase Ib/II trial for agitation in dementia. ENPP1 deficiency is a rare, chronic, systemic, and progressive disease.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

JANUARY 23, 2023

It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. Over 70, you have a one in three chance of dementia: over 80, it’s a one in two chance.

Life Science 98

Life Science Drugs Medicine Pharma Companies 98

XTalks

AUGUST 23, 2021

This is not a debate on approval,” said Stacie Weninger, PhD, president of the F-Prime Biomedical Research Initiative, in a focused topic session on the impact of drug approval on future clinical trials held on Tuesday July 27. Now that [aducanumab] is approved, how will this affect clinical trials going forward?”.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

The Pharma Data

JULY 23, 2021

Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Food and Drug Administration (FDA) as a treatment for Alzheimer’s disease, as well as its broader Alzheimer’s disease portfolio and research in the field.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

Intouch Solutions

DECEMBER 6, 2021

Crabill agrees, saying “Virtual reality as a healthcare solution is a particularly interesting facet of this — a step outside of the massively discussed topic of telehealth! — and especially important as a treatment option for psychiatric disorders like PTSD, anxiety, and dementia.”

Marketing 52

Marketing Branding Sales Clinical Trials 52

The Pharma Data

DECEMBER 4, 2020

4, 2020 — Alzheimer disease and related dementias (ADRDs) are associated with adverse financial events years prior to clinical diagnosis, according to a study published online Nov. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. Professional. FRIDAY, Dec. © 2020 HealthDay.

Development 52

Development Medicine Research 52

The Pharma Data

NOVEMBER 4, 2020

million DALYs), Alzheimer disease and other dementias (2.55 Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. million DALYs), and migraine (2.40 million DALYs). Several authors disclosed financial ties to the biotechnology and pharmaceutical industries. Abstract/Full Text.

Research 52

Research 52

WCG Clinical

APRIL 18, 2023

Her aunt, Diane, was diagnosed with colon cancer; her sister, Renee, was diagnosed with multiple sclerosis; and her mother was diagnosed with dementia. Veney’s mother was diagnosed with dementia at 77. He simply said, “You’re in the beginning stages of dementia.” Then 2006 brought what she calls the “trifecta.”

Clinical Trials 64

Clinical Trials Clinical Trials Trials Doctors 64

Delveinsight

AUGUST 10, 2020

Medical Marijuana is a hot topic, a term with never-ending debate. Every time the topic broils, several questions arise. Once a fiber crop to the agriculturist, and a remedy of pain to physicians, now Cannabis was akin to an object of a criminal offense. Back to the times where it is not less than a Pariah. Is it safe to use?

Marketing 96

Marketing Clinical Trials Clinical Trials Pharma Companies 96

Pharma Marketing Network

OCTOBER 27, 2020

Don ( PMN): That’s interesting as you approach topics like this as an author how do you ensure that the content stays mostly evergreen or is that even a concern for you is it better that it doesn’t and you can come out with a version 2.0 the same book and improve upon the the initial thoughts and musings on these technologies.

Insulin 52

Insulin Marketing Doctors Doctor 52

Pharma Marketing Network

OCTOBER 27, 2020

Don ( PMN): That’s interesting as you approach topics like this as an author how do you ensure that the content stays mostly evergreen or is that even a concern for you is it better that it doesn’t and you can come out with a version 2.0 the same book and improve upon the the initial thoughts and musings on these technologies.

Insulin 52

Insulin Doctors Doctor Marketing 52

XTalks

FEBRUARY 11, 2021

Without the inclusion of Franklin’s opinion on the topic, it was agreed that the DNA model would be published as the work of Watson and Crick, while supporting data from Wilkins and Franklin was published as two separate papers. It still remains unclear whether Franklin’s work was accessed and interpreted with or without rightful permissions.

Genetics 119

Genetics DNA Genome Genomics 119